Experimental drug combo targets tough blood cancers
NCT ID NCT01905813
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 26 times
Summary
This early-stage trial tested a new drug called INCB040093, alone or combined with itacitinib, in 121 adults with B-cell cancers that had come back or stopped responding to treatment. The main goal was to find safe doses and check for side effects. Researchers also looked for signs that the drugs might shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Study site
Birmingham, Alabama, United States
-
Study site
Jacksonville, Florida, United States
-
Study site
Ann Arbor, Michigan, United States
-
Study site
Rochester, Minnesota, United States
-
Study site
New York, New York, United States
-
Study site
Rochester, New York, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
INCB040093 (a PI3Kδ inhibitor) and itacitinib (a JAK1 inhibitor)
What this could lead to
If it works, this could point toward a new treatment option for people with B-cell cancers that have not responded to prior therapies.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, not on proving effectiveness. The drug may cause side effects or fail to shrink tumors in later studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.